Medical News

RSS

Inhibitex joins Russell 3000 Index

Inhibitex, Inc. announced today that the Company was added to the broad-market Russell 3000® Index, as well as its Microcap and Global Indexes, when Russell Investments reconstituted its comprehensive set of U.S. and global equity indexes on Friday June 25, 2010.

28 Jun 2010

ULURU, Strakan International divest interest in Zindaclin to Crawford Healthcare subsidiary

ULURU Inc. announced today that Strakan International Limited and ULURU have divested their respective interest in Zindaclin® to a subsidiary of Crawford Healthcare Limited, a pharmaceutical company based in England. Zindaclin® is a product for the treatment of acne which is outside the strategic focus of ULURU. This product was included in the technology package ULURU acquired when it was formed in 2005.

28 Jun 2010

FUJINON restructured into two subsidiaries

FUJIFILM Holdings America Corporation, today announced that FUJINON INC. will be restructured into two subsidiaries - one will report into FUJIFILM North America Corporation and the other into FUJIFILM Medical Systems U.S.A., Inc. This restructuring of Fujinon into two subsidiary companies will support Fujifilm's objective of strengthening its sales organizations to realize future growth.

28 Jun 2010

Medicare turns to more comprehensive tools to find fraud

Federal Times: The Recovery Board, which oversees the $275 billion economic stimulus package that was approved by the federal government in 2009, is using a software platform from Palantir Technologies, based in Palo Alto, Calif. "The software tool analyzes information contained on various government-maintained databases — GSA's list of suspended or debarred contractors, the Treasury Department's financial crimes network and other law enforcement records — along with open-source data such as newspaper articles, lawsuits and other public documents.

28 Jun 2010

FDA grants Abbott 510(k) clearance to market molecular diagnostic test for detection of chlamydia, gonorrhea

Abbott announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration to market a new, sensitive molecular diagnostic test and instrument to simultaneously detect two of the nation's most prevalent sexually transmitted diseases (STDs), gonorrhea and chlamydia, including a new variant strain of chlamydia recently discovered in Sweden.

28 Jun 2010

KHN column: The Medicare 'doc fix': How to make political lemonade

In his latest Kaiser Health News column, Austin Frakt writes: "The mechanism that governs the growth rate of Medicare spending on physician services isn't working.

28 Jun 2010

Zeria reports positive results from Japanese Phase III study of Z-338 for functional dyspepsia

Zeria Pharmaceutical announced today positive results of their Japanese Phase III study of Z-338 (acotiamide hydrochloride hydrate; "acotiamide") for the treatment of functional dyspepsia (FD). FD is a gastrointestinal disease comprised of subjective symptoms including postprandial fullness, early satiation and epigastric pain without any organic abnormality on gastrointestinal tract.

28 Jun 2010

Instant processing of insurance claims possible during doctor visit

The New York Times has a consumer health column on programs that would process a patient's insurance claim: "Here's how it could work: A claim is generated and submitted electronically before you finish tying your shoes. By the time you reach the checkout desk, your doctor has received a payment commitment from your insurance company, just as Visa and MasterCard provide to a merchant after a customer swipes a card. It's not fantasy.

28 Jun 2010

Marinomed, Boehringer Ingelheim sign licensing agreement for common cold anti-viral nasal spray

Marinomed Biotechnologie GmbH, a company focused on the development of innovative therapies for respiratory diseases, announced today that it has signed a licensing agreement with the international pharmaceutical company Boehringer Ingelheim. The deal will aim to further extend marketing of Marinomed's anti-viral nasal spray for the treatment of the Common Cold to all of Europe (except Austria and UK), Russia and CIS, South America, parts of Asia and Australia.

28 Jun 2010

Emerald, FORMA sign strategic partnership for structure-based design of cancer drug candidates

Emerald BioStructures, a leading provider of integrated structural biology services, and FORMA Therapeutics, a drug discovery company, today announced the signing of a strategic partnership for the structure-based design of cancer drug candidates for FORMA's pipeline.

28 Jun 2010

Fate Therapeutics recognized with Red Herring's North America 100 award

Fate Therapeutics, Inc. announced today that the Company received Red Herring's North America 100 award, a prestigious list honoring the year's most promising private and innovative companies from the North American business region. The nominees were evaluated by the Red Herring editorial team on both quantitative and qualitative criteria, such as financial performance, technology innovation, quality of management, execution of strategy and integration into their respective industries.

28 Jun 2010

Pain Therapeutics modifies strategic alliance with King Pharmaceuticals for REMOXY outside U.S.

Pain Therapeutics, Inc. announced today a modification of its strategic alliance with King Pharmaceuticals, Inc. for REMOXY outside the U.S. The move signals a desire to target Europe's small and growing market for strong pain medications.

28 Jun 2010

Conmed signs agreement with City of Roanoke to provide correctional facility health care services

Conmed Healthcare Management, Inc., a leading full service provider of correctional facility healthcare services to county detention centers, today announced that it has signed an agreement with the City of Roanoke, VA, for an initial three-year term with options for two one-year extensions which are at the City's option.

28 Jun 2010

Boston Therapeutics submits structure, function claims of SUGARDOWN to FDA

Boston Therapeutics, Inc. has announced that it has submitted structure and function claims of its SUGARDOWN™ to the US Food and Drug Administration on June 21, 2010.

28 Jun 2010

BioSante joins Russell 3000 Index

BioSante Pharmaceuticals, Inc. today announced it has been added to the broad-market Russell 3000 Index as part of Russell Investments' recent reconstitution of its comprehensive set of U.S. and global equity indexes which occurred after market close on June 25, 2010.

28 Jun 2010

Masimo granted FDA clearance for Pronto-7 noninvasive hemoglobin spot-check testing device

Masimo, the inventor of Masimo Rainbow Pulse CO-Oximetry™, Masimo Rainbow Acoustic Monitoring™, and Masimo SET® Measure-Through Motion and Low Perfusion pulse oximetry, today announced FDA 510(k) clearance for the Pronto-7™—a new handheld device designed for quick and easy noninvasive hemoglobin (SpHb®) spot-check testing, along with SpO2, pulse rate, and perfusion index, in virtually any environment.

28 Jun 2010

Eisai, Morphotek receive clearance for MORAb-022 Phase I clinical trial for rheumatoid arthritis

Eisai Inc. and Morphotek®, Inc. announced today that the Medical Ethical Review Committee and Central Committee on Research Involving Human Subjects of the Netherlands cleared its Clinical Trial Application to test the investigational new drug MORAb-022 in a Phase I clinical trial that will include both normal healthy volunteers and subjects diagnosed with rheumatoid arthritis.

28 Jun 2010

MorphoSys, Xencor sign worldwide exclusive license, collaboration agreement for XmAb5574 antibody program

MorphoSys AG and US-based biopharmaceutical company Xencor, Inc., announced today the signing of a worldwide exclusive license and collaboration agreement for an antibody in Phase 1 clinical development. The agreement provides MorphoSys with an exclusive worldwide license to XmAb5574, a high potency monoclonal antibody developed by Xencor for the treatment of B-cell malignancies.

28 Jun 2010

Aestus Therapeutics announces license agreement with Astellas Pharma

Aestus Therapeutics, Inc. announced today a license agreement with Astellas Pharma Inc. (Astellas; Tokyo, Japan) to provide Aestus with exclusive, world-wide rights to the Astellas product FK614. Aestus will develop the product as ATx08-001, a novel, first-in-class therapeutic for the treatment of neuropathic pain. The first clinical trial will start later this year.

28 Jun 2010

Clinical study results show no increased risk of CV events associated with SYMLIN injection

Amylin Pharmaceuticals, Inc. today announced results from an analysis of an integrated database of clinical studies that showed no increased risk of cardiovascular events associated with SYMLIN (pramlintide acetate) injection use compared to a pooled comparator group treated with either placebo or rapid-acting insulin. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association in Orlando, Fla.

28 Jun 2010

Medical News

Inhibitex joins Russell 3000 Index

ULURU, Strakan International divest interest in Zindaclin to Crawford Healthcare subsidiary

FUJINON restructured into two subsidiaries

Medicare turns to more comprehensive tools to find fraud

FDA grants Abbott 510(k) clearance to market molecular diagnostic test for detection of chlamydia, gonorrhea

KHN column: The Medicare 'doc fix': How to make political lemonade

Zeria reports positive results from Japanese Phase III study of Z-338 for functional dyspepsia

Instant processing of insurance claims possible during doctor visit

Marinomed, Boehringer Ingelheim sign licensing agreement for common cold anti-viral nasal spray

Emerald, FORMA sign strategic partnership for structure-based design of cancer drug candidates

Fate Therapeutics recognized with Red Herring's North America 100 award

Pain Therapeutics modifies strategic alliance with King Pharmaceuticals for REMOXY outside U.S.

Conmed signs agreement with City of Roanoke to provide correctional facility health care services

Boston Therapeutics submits structure, function claims of SUGARDOWN to FDA

BioSante joins Russell 3000 Index

Masimo granted FDA clearance for Pronto-7 noninvasive hemoglobin spot-check testing device

Eisai, Morphotek receive clearance for MORAb-022 Phase I clinical trial for rheumatoid arthritis

MorphoSys, Xencor sign worldwide exclusive license, collaboration agreement for XmAb5574 antibody program

Aestus Therapeutics announces license agreement with Astellas Pharma

Clinical study results show no increased risk of CV events associated with SYMLIN injection

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News